TY - JOUR
T1 - Mechanistic bottom-up estimation of passive drug absorption from the gastrointestinal tract
T2 - Comparison among primary cultured human intestinal cells, Caco-2 cells, artificial membrane, and animal scale-up
AU - Tsuchitani, Toshiaki
AU - Akiyoshi, Takeshi
AU - Imaoka, Ayuko
AU - Ohtani, Hisakazu
N1 - Funding Information:
This research was not supported by any funding sources ?
Publisher Copyright:
©2022 Dustri-Verlag Dr. K. Feistle.
PY - 2022/5
Y1 - 2022/5
N2 - Objective: The fraction of drug absorbed (Fa) from the intestine is an important parameter to characterize the pharmacokinetics of a drug. We aimed to search for an experimental system that provides the best parameters for estimating the effective permeability (Peff) used for the bottom-up prediction of Fa. Materials and methods: The absorption kinetics of 12 passively absorbed drugs were simulated by a compartment absorption transit (CAT) model using absorption parameters from four different experimental systems: human intestinal epithelial cell (HIEC) monolayer, Caco-2 monolayer, parallel artificial membrane permeability assay (PAMPA), and in situ rat intestinal perfusion. All absorption parameters were obtained from the literature. The in vitro apparent permeability coefficient (Papp) and rat in situ Peff were converted to human Peff using a bottom-up approach for each region, based on the morphological features of the human intestine. The simulated Fa values were compared to the respective observed values. Furthermore, plasma concentration profiles of the drugs were simulated by convolution using the time-course of the absorption rate simulated using the Peff values calculated from the HIEC Papp. Results: The Fa values were best predicted by using the Peff values calculated from HEIC, within a 1.3-fold range of observed Fa in 11 out of 12 drugs. The simulated Cmax values of pharmacokinetic simulation using HIEC Papp fell within a 1.5-fold range of observed values for all the drugs examined. Conclusion: The HIEC monolayer was identified as the most suitable permeation parameter for estimating Fa and Cmax using a morphological feature-based bottom-up approach.
AB - Objective: The fraction of drug absorbed (Fa) from the intestine is an important parameter to characterize the pharmacokinetics of a drug. We aimed to search for an experimental system that provides the best parameters for estimating the effective permeability (Peff) used for the bottom-up prediction of Fa. Materials and methods: The absorption kinetics of 12 passively absorbed drugs were simulated by a compartment absorption transit (CAT) model using absorption parameters from four different experimental systems: human intestinal epithelial cell (HIEC) monolayer, Caco-2 monolayer, parallel artificial membrane permeability assay (PAMPA), and in situ rat intestinal perfusion. All absorption parameters were obtained from the literature. The in vitro apparent permeability coefficient (Papp) and rat in situ Peff were converted to human Peff using a bottom-up approach for each region, based on the morphological features of the human intestine. The simulated Fa values were compared to the respective observed values. Furthermore, plasma concentration profiles of the drugs were simulated by convolution using the time-course of the absorption rate simulated using the Peff values calculated from the HIEC Papp. Results: The Fa values were best predicted by using the Peff values calculated from HEIC, within a 1.3-fold range of observed Fa in 11 out of 12 drugs. The simulated Cmax values of pharmacokinetic simulation using HIEC Papp fell within a 1.5-fold range of observed values for all the drugs examined. Conclusion: The HIEC monolayer was identified as the most suitable permeation parameter for estimating Fa and Cmax using a morphological feature-based bottom-up approach.
KW - absorption – permeability
KW - extrapolation – CAT model
KW - in vitro-to-in vivo
KW - simulation – drug
UR - http://www.scopus.com/inward/record.url?scp=85133102806&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133102806&partnerID=8YFLogxK
U2 - 10.5414/CP204172
DO - 10.5414/CP204172
M3 - Article
C2 - 35343429
AN - SCOPUS:85133102806
SN - 0946-1965
VL - 60
SP - 217
EP - 224
JO - International journal of clinical pharmacology and therapeutics
JF - International journal of clinical pharmacology and therapeutics
IS - 5
ER -